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Fibrates (anti-hyperlipidemic agents) enhance the mRNA expression of uncoupling protein 2 (UCP2) in the liver and that of uncoupling
protein 3 (UCP3) in skeletal muscle in standard-diet-fed rats and induce a de novo expression of UCP3 (mRNA and protein) in the liver of
high-fat-fed rats. Here, we report that in the liver of normal rats, fenofibrate induces a de novo expression of UCP3 and a 6-fold increase in
UCP2 mRNA, whereas UCP2 protein was not detectable. Indeed, we evidenced an ORF in UCP2 exon 2 potentially able to inhibit the
expression of the protein. Fenofibrate increases the expression and activity of hepatic enzymes and cofactors involved in lipid handling and
UCP3 activity and, as is the case for UCP3, induces other muscle-specific genes (e.g., Carnitine palmitoyl transferase 1b and Ubiquinone
biosynthesis protein COQ7 homolog). In addition, we demonstrated that in mitochondria from fenofibrate-treated rats a palmitoyl-carnitine-
induced GDP-sensitive uncoupling takes place, involving UCP3 rather than other uncouplers (i.e., UCP2 and Adenine Nucleotide
Translocase). Thus, the liver of fenofibrate-treated standard-diet- fed rat is a useful model for investigations of the biochemical functions of
UCP3 and allowed us to demonstrate that fenofibrate programs a gene-expression pattern able to modulate lipid handling and UCP3
activation.
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Fenofibrate, a synthetic fibric acid derivative, is a pro-drug
that is rapidly hydrolyzed in vivo to form fenofibric acid, whichAbbreviations: UCPs, Uncoupling proteins 1, 2, 3; HDMCP, Hepatocellular
Carcinoma Downregulated Mitochondrial Carrier Protein; MTE-I, mitochon-
drial thioesterase 1; PPAR, Peroxisome Proliferator-activated Receptor; FA,
fatty acid; ROS, reactive oxygen species; ORF, open reading frame; CAT,
CarboxyAtracTilate; CoQ, Coenzyme Q; CPT, Carnitine Palmitoyl Transferase;
ACS, Acyl CoA Synthetase; LPL, Lipoprotein Lipase; COQ7, Ubiquinone
biosynthesis protein COQ7 homolog; HMGR, 3-hydroxy-3-methylglutaryl
coenzyme A reductase; AdNT, adenine nucleotide translocase
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doi:10.1016/j.bbabio.2006.02.016is a highly effective agent for the treatment of dyslipidemias [1].
Fenofibrate acts as a nuclear peroxisome proliferator-activated
receptor α1 (PPAR-α) ligand, thereby promoting increased
hepatic fatty acid oxidation as well as an increased catabolism
and reduced synthesis/secretion of triglycerides [2–6]. Fenofi-
brate-activated PPAR-α has also been suggested to be involved
in the regulation of energy balance on the grounds that it
prevents or reduces body-weight gain in rodent genetic models
of obesity [7,8] as well as in diet-induced obese rodents [9–12].
Stimulatory effects of PPAR-α agonists on peroxisomal and
mitochondrial fatty acidβ-oxidation have been described in both
liver and muscle [6], and in a recent study, we demonstrated that
fenofibrate enhanced hepatic mitochondrial and peroxisomal FA
oxidation, leading to a slight increase in resting metabolic rate
[9]. Previous studies have also shown that fenofibrate stimulates
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16]. These proteins, which are mitochondrial anion carriers
located in the inner membrane, are potentially able to lower the
proton electrochemical gradient, permitting H+ to bypass the
ATP synthase complex and so generate heat and waste some
energy. However, this mechanism is well established only for
UCP1 (present in brown adipose tissue), the physiological role
of which is to mediate a regulated, thermogenic proton leak in
response either to cold or to diet [17].
For UCP2 and UCP3, however, the above function seems
unlikely, and several hypotheses [18–26] have been put
forward including: (1) modulating the production of reactive
oxygen species (ROS) and limiting or preventing their
deleterious effects, (2) being involved in lipid metabolism,
(3) preventing lipotoxicity, (4) being involved in glucose
homeostasis, and (5) modulating energy expenditure. With
regard to UCP3 and its putative involvement in lipid
metabolism, a role as a regulator of the use of lipids as a
fuel substrate has been postulated in situations in which lipid
metabolism predominates [23,24]. In this context, we have
shown that, in the liver of fat-fed rats, the de novo expression
of UCP3 that is induced by fenofibrate treatment is associated
with enhancements of both fatty acid metabolism and the
expression of mitochondrial thioesterase 1 (MTE-I), an
enzyme that catalyzes the hydrolysis of acyl-CoAs to free
fatty acid anions and CoASH [16,25]. However, in the
presence of the de novo expressed UCP3, the observed lack
of an enhanced basal uncoupling activity (i.e., in the presence
of BSA to chelate endogenous FA) led us to suggest that
reducing mitochondrial efficiency is not the primary function
of UCP3 in the liver of fat-fed, fenofibrate-treated rats [16].
This conclusion was based on the fact that the interpretation
of many of the experiments assumes that UCP3 catalyses a
basal proton leak across the inner mitochondrial membrane
without the need for other cofactors. This assumption,
however, now seems to be incorrect. Indeed, it is becoming
increasingly evident (i) that an inducible proton conductance,
rather than a basal one, can be catalyzed by UCP3, and that
in vitro it may be regulated by cofactors such as CoQ, ROS,
and lipids (and/or their derivatives) [27,28], and (ii) that in
view of the above, UCP3 could display some thermogenic
capacities [29].
In the present paper, we addressed this issue by examining,
in the liver of normal rats, the effects of fenofibrate on the
biochemical pathways and gene-expression pattern of
enzymes and cofactors involved both in lipid handling and
in the activity of UCP3. To this aim, to attribute the
biochemical modifications induced by fenofibrate to UCP3,
we had to exclude the possible involvement of UCP2. UCP2
mRNA, in fact, is induced by fenofibrate [14], and in some
contexts, UCP2 has been shown to be able to uncouple
mitochondria in a GDP-sensitive manner. Since the presence
of a UCP2 transcript does not necessarily correspond to
UCP2 protein [30], we measured the mitochondrial levels of
the protein, and having found it to be absent, we performed
direct sequencing of UCP2 cDNA to assess the putative
presence of a cis-downregulation mechanism like that alreadyreported in human and mouse tissues [30]. Moreover, we
searched whether the recently cloned hepatocellular carcino-
ma downregulated mitochondrial carrier protein (HDMCP, a
liver-specific anion-carrier endowed with uncoupling proper-
ties when ectopically expressed [31]) and adenine nucleotide
translocase (AdNT, another mitochondrial carrier with the
potential to uncouple mitochondrial respiration [32]) might be
involved in the effects exerted by fenofibrate.
In addition, since non-constitutively expressed protein (i.e.,
UCP3), can be induced by fenofibrate, we asked, whether to
support the marked metabolic adaptation in the liver, other
proteins of a “non-hepatic” origin might be induced by
fenofibrate, too.
2. Materials and methods
2.1. Materials
A polyclonal antibody raised against the C-terminal region of human UCP3
protein (AB3046) was purchased from Chemicon International (Temecula, CA),
while one raised against the C-terminal region of human UCP2 protein (UCP2
C-20) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Sensitivity and specificity of the above UCP2 and UCP3 antibodies have
been examined in several tissues from UCPs knockout mice [33–35]. A
mitochondrial thioesterase I (MTE-I) antibody was kindly provided by Dr.
Stefan Alexson (Karolinska Institute, Huddinge, Sweden). Fenofibrate and other
chemicals were all from Sigma Aldrich S.r.l., (St. Louis, MO) except
carboxyatractilate (CAT), which was from Calbiochem (Vwr International Srl,
Italy). The primers used for RT-PCR analysis were purchased from Sigma
Genosys (Cambridge, UK).
2.2. Animals and treatments
Two groups of male Wistar rats (250–300 g) (Charles River, Lecco, Italy)
(each consisting of 3 animals) were used throughout: namely, normal rats
(referred to as N) and fenofibrate-treated rats (referred to as Fe). For 10 days, Fe
rats were treated orally once a day at a dose of 320 mg/Kg body weight with
fenofibrate suspended in 1% carboxymethylcellulose [36,37], whereas N rats
were dosed with 1% carboxymethylcellulose alone. At the end of the treatment,
the rats were anesthetized, then killed by decapitation. The liver was excised,
weighed, and either immediately processed for the preparation of mitochondria
or immediately frozen in liquid nitrogen and stored at −80 °C for later
processing. All experiments were performed in accordance with general
guidelines regarding animal experiments and were approved by our institutional
committee for animal care.
2.3. RNA isolation and RT-PCR assays
Total RNAwas isolated using a protocol based on one originally described
by Chomszynski and Sacchi [38]. RT-PCR was performed slightly differently
from a previous study from us [9], as different primers for UCP2 and other PCR
conditions have been used accordingly to [39]. The primers used are listed in
Table 1.
Separation of the PCR-products was performed on a 2% agarose gel
containing ethidium bromide. The products were readily visualised, and they
were quantified by means of a Bio Rad Molecular Imager FX using the supplied
software (QuantityOne; Biorad). Expression signals for the genes were
normalized with respect to the non-regulated β-actin signal.
2.4. Sequence analysis of upstream UCP2 repressor/ORF
Rat liver total RNA was reverse-transcribed as described in the previous
section. The UCP2 cDNA fragment comprising the repressor ORF was
amplified using the following mouse oligonucleotide primers: sense, 5′-
Table 1
Oligonucleotide primers used for RT-PCR experiments
Gene Sense oligonucleotide Antisense oligonucleotide
UCP3 5′-ATGGATGCCTACAGAACCAT-3′ 5′-CTGGGCCACCATCCTCAGCA-3′
UCP2 5′-CCTTCTGCACTCCTGTGTTC-3′ 5′-GTGGCCTTGAAACCAACCAT-3′
HDMCP 5′-GCCACTCCTTTGCCACCTAC3′ 5′-CACAGCCTCATAAGCCACGA-3′
AdNT1 5′-TGCTCAAGTTCACAGGTTCAC -3′ 5′-CTTCTGTTTGCTGTGGAATC -3′
AdNT2 5′-GGACAGATTCTCTGGGCTTG -3′ 5′-TGGAAATGGCTTTAAGAGAAAAC -3′
LPL 5′-TCATCAACTGGCTGGAGGAAG-3′ 5′-TATGCCTTGCTGGGGTTTTCT-3′
ACS 5′-AACACGTCAGTGAAGCGATG-3′ 5′-AACACATTTGCCCCTTTCAC-3′
CPT1a′ 5′-ATGTGGACCTGCATTCCTTC-3′ 5′-CCTTCAGGAAAGGTGAGTCG-3′
CPT1b 5′-CTCAGCCTCTACGGCAAATC-3′ 5′-CTTCTTGATCAGGCCTTTGC-3′
CPT2 5′-GTGGCAAGGAGTTCCTGAAG-3′ 5′-TGGTTCATCTGCTGGTATGC-3′
MTE-I 5′-CCTCGTCTTTCGCTGTCCTG-3′ 5′-GTGTCCGTCCAGCACCTCCA-3′
HMGR 5′-GAAGCTATGGTTGACGTAAAC-3′ 5′-GCTTGCTGAGGTAGAAGGTTG-3′
COQ7 5′-TGGAGGAGGACGCTGAGAAG-3′ 5′-GTGACACAACCCCAAACACC-3′
β-actin 5′-TTGTAACCAACTGGGACGAT-3′ 5′-TAATGTCACGCACGATTTCC-3′
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CAACCAT-3′. The same oligonucleotides were utilized for direct sequencing
using a commercially available sequencing kit (USB Sequenase PCR product
sequencing kit; Amersham Life Science Corp, Arlington Heights, IL).
2.5. Preparation of mitochondria and assays
Liver mitochondria were isolated by differential centrifugation as previously
reported [9] and used immediately either for an assay of respiration rate and
membrane potentials or for enzymatic assays, or else immediately stored at
–80 °C for later processing. For HPLC analysis, samples of the homogenate
were mixed with 0.1 M aqueous SDS, with ethanolic BHT (10 mg/ml) being
added to prevent lipid autoxidation without reducing the ubiquinones (as
reported by Lang and Packer [40]). Western immunoblot analyses were carried
out according to Laemmli [41] as described in [16]. The protein concentration
was determined by the method of Hartree [42].
CPT-system activity and acyl-CoA-thioesterase activity were measured
spectrophotometrically according to Alexson and Nedergaard [43]. For both
enzymes, palmitoyl-CoA was used at saturating concentrations (50 μM). As
CPT-system activity is defined as the carnitine-dependent CoA production due
to the overt (outer membrane, CPT1) and latent (inner membrane, CPT2)
enzyme activities, it was determined in the presence of both palmitoyl-CoA and
saturating carnitine (5 mM).
Mitochondrial aconitase activity was measured according to Hanselden
and Fridovich [44]. Briefly, mitochondrial proteins were incubated in 1%
Triton x-100 and resuspended in 50 mM Tris–HCl (pH 7.4), 30 mM
isocitrate, 0.2 mM NADP, and 2 Units of isocitrate dehydrogenase. Enzyme
activity (at 340 nm) corresponds to the active aconitase. Aconitase inhibited
by ROS in vivo was reactivated so that total activity could be measured
with 0.5 M dithiothreitol, 20 mM Na2S, and 20 mM ferrous ammonium
sulfate. The activity measured after such reactivation corresponds to the total
aconitase activity. Mitochondrial CoQ was extracted and quantified by
HPLC, as described by Takada et al. [45,46]. The concentrations of CoQ9
and CoQ10 obtained represent the sum of the respective quinone and quinol
forms. The accurate concentration of each standard solution was determined
spectrophotometrically using molar extinction coefficients published previ-
ously [47].
2.6. Measurement of respiration rate and membrane potential (ΔΨ)
Mitochondrial fatty acid oxidation rate was determined polarographically by
means of a Clark-type electrode. Mitochondria were incubated at 30 °C in a
respiration medium consisting of 80 mM KCl, 50 mM HEPES (pH 7), 1 mM
EGTA, 5 mM K2HPO4, and 1% BSA, supplemented with 2.5 mM malate and
120 μg/ml ADP. After a 2–3 min incubation, the reaction was started by the
addition of palmitoyl-L-carnitine (40 μM). Respiration rate and membrane
potential were measured simultaneously, the latter being detected using atriphenylmethylphosphonium (TPMP+)-sensitive electrode. To this end, 0.5 mg
mitochondrial proteins were incubated in 1 ml standard incubation medium
supplemented with 5 μM rotenone, 1 μg/ml oligomycin, 80 ng/ml nigericin, and
15 μg/ml carboxyatractylate (CAT), the last being added to exclude the
contribution of adenine nucleotide translocase (AdNT). BSAwas used to chelate
the endogenous FA pool. The electrode was calibrated by means of sequential
additions up to 4 μM TPMP+. Then, mitochondria were energized using 6 mM
succinate, and respiration was titrated with increasing amounts of palmitoyl-
carnitine (up to 40 μM), as previously reported [48]. Palmitoyl-carnitine has
been used as substrate for the intramitochondrial production of fatty acid anions
(i.e., palmitoyl CoA via acyl-CoA thioesterase activity), while succinate has
been used as a saturating substrate in the presence of rotenone to preserve the
possible influences on respiration and/or membrane potential due to the
formation of the reduced coenzymes produced by complete palmitoyl CoA
oxidation. The above determination was performed both in the presence and in
the absence of exogenous GDP (500 μM). At the end of each run, respiration
rate and membrane potential were measured after addition of 0.2 μM carbonyl
cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP), which causes complete
dissipation of the membrane potential and allows us to evaluate: (i) the amount
of TPMP+ released back into the medium, (ii) any small electrode drift, and (iii)
how much respiration can be still stimulated. A TPMP+ -binding correction of
0.4/(μl per mg protein) was applied for mitochondria from each group of
animals.
2.7. Statistical analysis
The statistical significance of differences between the two groups of rats was
determined using a Student's t-test, P values less than 0.05 being considered
statistically significant.3. Results
3.1. Expressions of UCP2, UCP3, HDMC, and AdNT
In the liver of normal rats, fenofibrate treatment induced a de
novo expression of UCP3 mRNA (Fig. 1A) and increased the
UCP2 mRNA level about 6-fold (Fig. 1A). The latter result
seems to be in contrast with our previous paper [16] in which no
variation in UCP2 mRNA was observed after fenofibrate
administration. However, the contrast may be more apparent
than real. Two possible reasons for the apparent discrepancy
may be noted as here we used: (1) a different diet regimen
(standard diet fed rats instead of high fat diet fed rats) that is
known to be able to influence gene expression and (2) different
489E. Silvestri et al. / Biochimica et Biophysica Acta 1757 (2006) 486–495primers and PCR conditions for analysis of UCP2 mRNA
levels, (see Materials and methods). No influence was observed
on the mRNA expressions for either HDMCP or AdNT [(both
the ubiquitous and muscle-specific isoforms, AdNT2 and
AdNT1, respectively) (data not shown). Western blot analysis
revealed that the liver mitochondria from Fe rats contained
UCP3 protein (Fig. 1B), but UCP2 protein was not detected
(Fig. 1B). Direct sequencing of UCP2 cDNA revealed that exon
2 shares a very high homology with the corresponding region of
the mouse and human UCP2 genes (Fig. 1C). Pecqueur et al.
[30] reported that exon 2 of the mouse UCP2 gene contains a
short open reading frame (ORF1) encoding a putative peptide of
36 amino acids that is able to mediate cis-downregulation of theFig. 1. Uncoupling Protein 3 (UCP3) and Uncoupling Protein 2 (UCP2) mRNA
levels and mitochondrial protein density in liver of control (N) and fenofibrate-
treated (Fe) rats. (A) RT-PCR-based measurements of UCP3 and UCP2 mRNAs
in liver. Gastrocnemius and spleen were used as positive controls for UCP3 and
UCP2 expressions, respectively. Lower panel: quantification of the data for
UCP2 expression shown in the upper panel. Data are expressed relative to the
value obtained for N liver, which was set as 1, and are presented separately for
each treatment (as indicated below the bars). Error bars represent S.D. of the
mean (n=3). Bars labeled with dissimilar letters are significantly different
(P<0.05). (B) Western immunoblot analysis of UCP3 and UCP2 protein levels
in liver mitochondria. Gastrocnemius and spleen mitochondrial proteins were
loaded as UCP3 and UCP2 positive controls, respectively. (C) Amino acid
sequence alignment for the repressor peptide encoded by Open Reading Frame 1
(ORF1) of the UCP2 gene of rat, mouse, and human. The three methionines (M)
in the repressor are underlined and the three corresponding regions 1, 2, and 3
are marked above. Roman numerals indicate the exons in UCP2 cDNA. Also
indicated are the four ATG positions.translation of the gene. Sequence alignment of rat, human, and
mouse UCP2 genes provided evidence that exon 2 of rat UCP2
contains an ORF with its sub-region 3 being identical to the
human and mouse ones (Fig. 1C), suggesting that an
homologous mechanism could be operative in the rat.
3.2. Expression of genes and biochemical pathways related to
lipid handling
A broad program of genes known to be involved in cellular
fatty acid import and utilization was activated by fenofibrate in
the liver of Fe rats. The expressions of genes encoding LPL and
ACS were upregulated by 36.7- and 9.7-fold, respectively (Fig.
2A and B). In parallel, the expression levels of CPT1a and
CPT2 were upregulated by 2.2- and 8.8-fold, respectively (Fig.
3A). It was noteworthy that, as was the case for UCP3,
fenofibrate induced a de novo expression of another skeletal
muscle-specific gene: CPT1b (Fig. 3A).
As predicted by this expression profile, the mitochondrial
CPT-system activity was significantly greater [+115% (Fig.
3B)] in Fe rats than in N rats. The mitochondrial fatty acid β-
oxidation rate was significantly higher (+61%) in liver
mitochondria isolated from Fe rats than in those from N rats
(P<0.05), the actual values [expressed in nAtoms O/min mg
protein) being 90±12 and 146±43 for N and Fe, respectively.
Fenofibrate treatment also affected MTE-I expression,
increasing both its mRNA [to about 4.5 times that in the
untreated controls (Fig. 4A) and its mitochondrial protein level
[to about 5.5 times that in the untreated controls (Fig. 4B)]. As
predicted by the expression profile, the mitochondrial acyl-
CoA-thioesterase activity was significantly greater [+82% (Fig.
4C)] in Fe rats than in N rats.
3.3. Mitochondrial uncoupling
The addition of palmitoyl-carnitine to succinate-energized
liver mitochondria from Fe rats simultaneously increased
respiration rate and decreased membrane potential (diagnostic
of mitochondrial uncoupling) (Fig. 5A, B, D, and E). These
effects were not detectable in mitochondria from N rats (Fig.
5A, B, D, and E). The respiration rates of N and Fe
Fig. 3. Carnitine Palmitoyl Transferase (CPT) mRNA levels and total CPT
activity in liver of N and Fe rats. (A) RT-PCR-based measurements of the
CPT1b, CPT1a, and CPT2 mRNA levels. Lower panels: quantification of the
data shown in the upper panels. Data are expressed relative to the value
obtained for N liver, which was set as 1, and are presented separately for each
treatment (as indicated below the bars). Error bars represent S.D. of the mean
(n=3). *P<0.05 vs. N. (B) CPT-system activity in mitochondria isolated from
liver of N and Fe rats. Results are each the mean±S.E.M. from 4 preparations.
*P<0.05 vs. N.
Fig. 2. Lipoprotein Lipase (LPL) and Acyl CoA Synthetase (ACS) mRNA levels
in liver of N and Fe rats. RT-PCR-based measurements of LPL (A) and ACS (B)
mRNA levels. Lower panels: quantification of the data shown in the upper
panels. Data are expressed relative to the value obtained for N liver, which was
set as 1, and are presented separately for each treatment (as indicated below the
bars). Error bars represent S.D. of the mean (n=3). *P<0.05 vs. N.
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each run, increased by about 3 and 4 times, respectively (Fig.
5A and B). At the same time, after FCCP addition the
membrane-potential decrease (represented as the TPMP+
release from mitochondria back into the medium) was lower
for mitochondria from Fe rats than for those from N rats (Fig.
5A and B, blue vertical line). These data support an uncoupling
effect of palmitoyl-carnitine in mitochondria from Fe rats. The
changes in both respiration rate and membrane potential
induced by palmitoyl-carnitine (whatever its concentration) in
Fe mitochondria were completely abolished by GDP (Fig. 5C,
D, and E). In contrast, GDP had no effect on mitochondria
from N rats (data not shown). Moreover, in the presence of
GDP, addition of FCCP led to an increase in respiration rate
and a decrease in membrane potential in Fe mitochondria that
were greater than the changes observed in the absence of GDP
(Fig. 5C and B, blue vertical lines). Taken as a whole, these
data demonstrate the involvement of UCP3 in the uncoupling
effect of palmitoyl-carnitine in mitochondria from the liver of
the Fe rat.3.4. In vivo mitochondrial ROS production
Aconitase activity, measured as an indicator of in vivo
ROS production, was significantly higher (+46%) in liver
mitochondria isolated from Fe rats than in those from N rats
(P<0.05), the actual values, expressed in ΔA/min mg protein,
Fig. 4. Mitochondrial Thioesterase 1 (MTE-I) mRNA levels, mitochondrial
protein density, and mitochondrial enzyme activity in liver of N and Fe rats.
(A) RT-PCR-based measurement of MTE-I mRNA. Lower panel shows
quantification of the signals shown in the upper panel (as described in Figs. 1
and 3). (B) Western immunoblot analysis of mitochondrial MTE-I protein
levels. Lower panel shows quantification of the signals shown in the upper
panel (as described in Figs. 1 and 3). Error bars represent S.D. of the mean
(n=3). *P<0.05 vs. N. (C) Acyl-CoA-thioesterase activity of liver
mitochondria isolated from N and Fe rats. Results are each the mean±S.E.
M. from 4 preparations. *P<0.05 vs. N.
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respectively (results are each the mean±S.E.M. from 4
preparations, P<0.05 vs. N).In addition, total aconitase activity, determined after in vitro
reactivation, was not different between the liver mitochondria
isolated from the two groups (data not shown). This suggests a
low degree of in vivo aconitase inhibition by ROS in
mitochondria from Fe-treated rats.
3.5. Mitochondrial CoQ levels
The amount of mitochondrial total CoQ (CoQ9+CoQ10) was
increased about 3.6-fold by fenofibrate treatment (Fig. 6A). The
liver HMGR and COQ7 expression levels were also affected,
HMGR expression being significantly reduced by about 17%
versus its level in N rats, while COQ7 expression was strongly
upregulated (Fig. 6B).
4. Discussion
Fenofibrate treatment is known to exert a hypolipidemic
effect by enhancing lipid catabolism in the liver, mainly
through a PPARα transcriptional induction of the genes for
mitochondrial and peroxisomal oxidative enzymes. Moreover,
its concomitant effect on the de novo expression of UCP3
supports a role for such a mitochondrial carrier in the
biochemical pathways linked to lipid mobilization and
utilization [25,26]. Previous studies indicate that the pharma-
cological actions of fenofibrate are mediated, at least in part,
through a regulation of the transcription of a number of genes
involved in lipid and lipoprotein metabolism [1]. As we
expected, the present results show that fenofibrate modulates
lipid metabolism by reducing the amount of fatty acids
available to the liver for triglyceride synthesis, with
lipoprotein lipolysis being affected via a strong induction of
liver LPL expression. In addition, fenofibrate enhanced the
expression of CPT1a and CPT2, and induced, as was also true
for UCP3, a de novo expression of the skeletal muscle-
specific CPT1b gene, concomitantly stimulating the mito-
chondrial fatty acid β-oxidation rate. It is well established that
CPT1a and CPT1b have markedly different kinetic properties
and intrinsic characteristics, with CPT1a having the lowest
Km for carnitine and the highest IC50 for malonyl-CoA [49].
The expression pattern of the two isoforms is plastic, and
responds both to physiological and developmental signals
[50]. The observed de novo expression of CPT1b in the liver
following fenofibrate treatment might be interpreted as an
additional mechanism that serves to potentiate the mitochon-
drial uptake of fatty acids in a situation in which the pressure
put upon the substrate by fatty acids exceeds their oxidation
rate. Indeed, the activity of the CPT system was found to be
significantly enhanced (+115%), pointing to a shift in liver
cellular metabolism toward a channeling of fatty acids in the
direction of an enhanced β-oxidation rate (+61%) at the
expense of triacylglycerol synthesis. Moreover, the increased
mRNA expression of ACS – an enzyme that prevents efflux
of tissue-incorporated fatty acids by converting them into
acyl-CoA-derivatives, hence rendering the FA-uptake process
unidirectional – further supports the effect of fenofibrate on
the biochemical pathways involved in lipid utilization by the
Fig. 5. Effect of palmitoyl-carnitine titration on respiration rate and membrane potential of succinate-energized liver mitochondria from N and Fe rats. Panels A–C,
representative recordings showing simultaneous measurements of mitochondrial respiration and membrane potential in liver from N (A) and Fe (B and C) rats. In each
panel, the black and red traces show the oxygen and TPMP+ concentrations, respectively. Liver mitochondria (0.5 mg/ml) were incubated at 37 °C in the oxygen
electrode chamber in a total volume of 1 ml of assay medium containing rotenone, nigericin, oligomycin, and CAT. The TPMP+ and reference electrodes were inserted
into the chamber, and calibrated using four sequential 1 μM additions up to 4 μM TPMP+ before succinate was added to 6 mM. As shown in the recordings, the
TPMP+ electrode indicated uptake of TPMP+ to equilibrium in response to the generation of a membrane potential following addition of succinate (where
indicated). Respiration rate and membrane potential were titrated by sequential additions of palmitoyl-carnitine (PC, where indicated) up to 40 μM. After that,
FCCP was added (as indicated) to dissipate the membrane potential completely, allowing evaluation of: i) the amount of TPMP+ released back into the medium,
ii) any small electrode drift, and iii) how much respiration could still be stimulated. GDP (where present) was added to the incubation medium before the
mitochondria (C). The vertical blue line in each panel represents the amount of TPMP+ released from the mitochondria back into the medium after FCCP
addition. Panels D and E, the values obtained from each titration were quantified, and respiration rate and membrane potential were plotted against the palmitoyl-
carnitine concentration. For each group, data are expressed relative to the value obtained in the absence of palmitoyl-carnitine (taken as 100%). Results are each
the mean±S.E.M. from 4 preparations. *P<0.05 vs. N.
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fenofibrate treatment, the fatty acid supply exceeds their
rate of oxidation [the fenofibrate-induced increase in CPT-
system activity being almost two times the increase in the
oxidation rate), such treatment will lead to an accumulation of
fatty acids within the mitochondrial matrix, unless a
compensatory mechanism exists. These results are in line
with the hypothesis that UCP3 may be involved in the export
of fatty acids and/or of their peroxidated derivatives, effects
that might represent a protective mechanism for the
mitochondrial matrix when the supply of fatty acids exceeds
their rate of oxidation [20,24].In this study, fenofibrate treatment enhanced the UCP2
mRNA level, but did not alter the gene expression of the
recently cloned HDMCP or that of AdNT1 plus AdNT2. While
the de novo-induced UCP3 mRNA expression was accompa-
nied by the presence of the protein in the mitochondrial fraction,
UCP2 protein was not detected, most likely due to the presence
of an inhibitory post-transcriptional mechanism. Indeed, our
sequence alignment of rat, human, and mouse UCP2 genes
indicated that the rat UCP2 gene shares a very high homology
with the region of the mouse and human UCP2 genes
containing the repressor sequence described by Pecqueur et
al. [30] in the mouse that encodes a putative peptide of 36 amino
Fig. 6. Total CoQ levels, and 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGR) and Ubiquinone biosynthesis protein COQ7 homolog
(COQ7) mRNA levels in liver of N and Fe rats. (A) Endogenous mitochondrial
content of total CoQ (CoQ9+CoQ10, in both quinol and quinone forms) as
determined by HPLC analysis of liver from N and Fe rats. Results are each the
mean±S.E.M. from 4 preparations. *P<0.05 vs. N. (B) RT-PCR-based
measurements of HMGR and COQ7 mRNA levels. Lower panels: quantifica-
tion of the data shown in the upper panels. Data are expressed relative to the
value obtained for N liver, which was set as 1, and are presented separately for
each treatment (as indicated below the bars). Error bars represent S.D. of the
mean (n=3). *P<0.05 vs. N.
493E. Silvestri et al. / Biochimica et Biophysica Acta 1757 (2006) 486–495acids able to mediate cis-downregulation of the translation of
the gene. Our data suggest that a similar mechanism could be
operative in rat liver, too.
Fenofibrate also affected MTE-I expression and increased
mitochondrial acyl-CoA-thioesterase activity, thus leading to
an enhanced availability of: (i) CoA, a lack of which would
lead to an inhibition of β-oxidation and of the Krebs-cycle,
and (ii) intra-mitochondrial fatty acid anions, which could be
involved in a possible UCP3-mediated uncoupling associated
with a higher rate of entry into the mitochondria of
activated FA, as allowed by the CPT system. Indeed,
using our system – in which the addition of palmitoyl-
carnitine to succinate+ rotenone-energized mitochondria
could provide FA inside the mitochondria by means of
palmitoyl CoA hydrolysis, potentially catalyzed by MTE-I
and an increased NADH level – palmitoyl-carnitine induced
mitochondrial uncoupling only in mitochondria from Fe rats,since it simultaneously induced an increase in the respiration
rate and a decrease in the membrane potential. As stated in
Introduction, in a previous study, in the presence of the de
novo expressed UCP3, we did not observe differences in the
kinetic responses of the proton leak to change in membrane
potential [16]. However, in the above-cited study, we
measured the basal proton leak (in the presence of BSA,
which chelates fatty acids) without addition of FA such as
palmitoylcarnitine. On the other hand, here we measured
inducible proton conductance in the presence of palmitoyl-
carnitine as a provider of FA inside the mitochondria which
are recognised as UCPs activators [27,28].
In the present study, in view of the presence of CAT in the
incubation medium and the absence of UCP2 protein, the
uncoupling effects are presumably attributable to UCP3. The
simultaneous increases inMTE-I expression/activity and UCP3-
mediated uncoupling would have effects on: (a) the modulation
of the levels of CoA in the matrix, (b) the mitochondrial FA
trafficking, and (c) the rate of ROS production, when FA
utilization is stimulated. In addition, the UCP3-mediated
uncoupling would result in a decrease in redox pressure by
reducing ROS production. Indeed, the production of ROS is
positively correlated with, and is very sensitive to, changes in
mitochondrial membrane potential [51]. The data on aconitase
activity reported here support this idea. The effect exerted by
fenofibrate on UCP3 activity may also be related to its actions on
some cofactors involved in UCP3-mediated uncoupling. Indeed,
fenofibrate modulates themitochondrial level of CoQ (one of the
intracellular cofactors for UCP3-mediated uncoupling both in
vitro and in vivo [27,48]) by affecting the pathways involved in
its biosynthesis. It was noteworthy that while decreasing the
expression levels of HMGR, which is known to be involved in
systemic CoQ synthesis, fenofibrate treatment significantly
upregulated the expression level of COQ7, which encodes a
mitochondrial protein necessary for intramitochondrial CoQ
synthesis [52,53]. In turn, its inhibition of HMGR and activation
of such a mitochondrial biochemical pathway would allow
fenofibrate to exert an inhibitory effect on cholesterol synthesis
(via HMGR), while at the same time increasing the mitochon-
drial levels of CoQ, thus demonstrating that the mitochondrial
hepatic levels of CoQ can be increased by fenofibrate in a
manner that is independent of changes in cholesterol synthesis.
As is the case for UCP3 and CPT1b, the COQ7 gene is
predominantly expressed in skeletal muscle and heart under
normal conditions [52]. Again, the upregulation of the
expression of such genes in liver, together with the same effect
on the known liver-specific ones, suggest the need for additional
mechanisms to support the action of fenofibrate at the
mitochondrial level. In conclusion, this study demonstrates
that in rat liver, fenofibrate induces a remodelling of the pattern
of gene expression that serves to modulate the biochemical
pathways related to lipid handling and UCP3 activation. It seems
evident that UCP3-mediated uncoupling depends on the
concomitant activation of several interrelated biochemical
pathways, and that the fenofibrate-treated standard-diet-fed rat
may be a useful model for investigations of the biochemical
functions of UCP3.
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